Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas

NCT03534180 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03534180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03534180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 21, 2018
Completion date
July 26, 2023
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma